看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
# x+ X2 _4 P) s2 Z# Z0 I: r. X2 h
$ q4 {0 Z! d/ C( ]8 `/ h3 g! R6 E- _ `- T+ N1 S0 W7 r# w
Currently available feasibility data for possible combination strategies.
+ d1 h8 h% K! D+ P$ s! R————————————————————————————————( m# Q k* a* q( d! W5 S
Combination Feasibility according to preliminary data 0 w" v ~/ g8 z; [. Y1 P5 j
——————————————————————————————————+ }( F" G0 n! F9 H% |: O' r8 t
Bevacizumab + sorafenib Yes, reduced dose 5 Y3 K; f( D4 O+ Y6 s$ \, n+ Q2 Z
Bevacizumab + sunitinib† No $ o4 f0 A; K# b# D) x2 A- l
Bevacizumab + temsirolimus Yes
: H* @ O: h. A+ \0 i1 X0 MBevacizumab + everolimus Yes
$ P! W6 M0 M2 ]- w" ySorafenib + sunitinib ?
+ {* A2 X1 ]3 ^1 lSorafenib + temsirolimus Yes, reduced dose
7 q$ z/ D5 _6 J( VSorafenib + everolimus Yes, reduced dose 5 U5 I. g. J% q0 ^6 {
Sunitinib + temsirolimus† No
% i; t2 R4 N! p$ R2 L4 NSunitinib + everolimus ?
1 D" z4 o4 I( k5 fTemsirolimus + everolimus ?
/ q4 F2 r( t: L; u% T- T+ `, O1 L————————————————————* L# y) C/ X; h$ u5 C3 d9 p
†Led to US FDA warning.) F2 f( C4 U7 [% C/ k. d
?: As yet unattempted combination.+ K' }, j2 z' O, Q
|